/
The governor was also given a $196.3 million tax package that includes a formula change for distributing cigarette tax revenues to boost funding for Tampa s Moffitt Cancer Center.
A bill that would crack down on people who make false claims about COVID-19 vaccines and personal protective equipment was formally sent Thursday to Gov. Ron DeSantis.
The bill (HB 9), a priority of House Speaker Chris Sprowls, R-Palm Harbor, stems from people using authentic-looking websites that falsely offer access to vaccines or personal protective equipment.
The measure would lead to felony charges for people who run such scams and would authorize the attorney general to seek injunctions to shut down websites or other platforms used to spread fraudulent information.
/
Moffitt Cancer Center would get $26.9 million annually starting next fiscal year and $38.4 million starting in the 2024-25 fiscal year, according to a Senate staff analysis.
Senate sponsor Ed Hooper, R-Clearwater, said in March that the additional money would help Moffitt Cancer Center build a new campus.
A tax package approved Friday by Florida lawmakers is expected to lead to the H. Lee Moffitt Cancer Center receiving millions of additional dollars each year.
The bill (HB 7061), includes changing a formula for distributing cigarette tax revenues. The Senate in March approved a stand-alone bill (SB 866) on the issue, with the change then included in a broad tax package negotiated by House and Senate leaders.
Cancer survivor, advocate brings home his own Lombardi Trophy
Joshua Rivera of Tampa was recognized with his own replica Super Bowl trophy by the Vince Lombardi Cancer Foundation.
and last updated 2021-05-03 16:06:56-04
TAMPA, Fla. â Winning the Vince Lombardi Trophy is the greatest achievement in football, but a Tampa man was awarded his own Lombardi for winning a whole different kind of battle.
âI was diagnosed with Ewing Sarcoma at the age of 27; it was October 2007,â said Joshua Rivera.
Rivera was given just a 15% chance to survive.
âWith the help of my family and my friends and above all my physicians, I was able to quickly put that data point behind me and really focus on getting better,â said Rivera.
Share:
Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study
Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene s Proprietary Lymphodepletion Regimen
ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May 19, 2021 at 2:30 p.m. PT/5:30 p.m. ET
SOUTH SAN FRANCISCO, Calif. and PARIS, April 28, 2021 (GLOBE NEWSWIRE) Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international pharmaceutical company, today announced that longer-term follow-up data from Allogene s dose escalation Phase 1 ALPHA study of ALL
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Allogene Therapeutics to Present Data from its Anti-CD19 AlloCAR T™ Therapy Program in .
Allogene Therapeutics, Inc.April 28, 2021 GMT
Longer Term Data from the ALLO-501 Phase 1 ALPHA Study to be Presented Alongside Initial Data from the Phase 1 ALLO-501A ALPHA2 Study
Separate Presentation to Include Safety and PK/PD Data on ALLO-647 Used in, Allogene’s Proprietary Lymphodepletion Regimen
ALLO-501A, Intended for a Potentially Pivotal Phase 2 Trial, Previously Granted FDA Fast Track Designation for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Allogene to Host Virtual CD19 Forum to Review ASCO Datasets on May 19, 2021 at 2:30 p.m. PT/5:30 p.m. ET